|Bid||217.50 x 1000|
|Ask||219.32 x 800|
|Day's Range||217.41 - 220.40|
|52 Week Range||136.44 - 228.19|
|Beta (3Y Monthly)||0.86|
|PE Ratio (TTM)||64.31|
|Earnings Date||Oct 21, 2019 - Oct 25, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||215.03|
In a move to develop medical devices faster, at a lower cost, and with a greater likelihood of a successful exit, Koa Accel today announced its launch as a next generation medical device accelerator. While mentorship and access to a modicum of business services is the cornerstone of most accelerators, Koa embeds an experienced team covering all of the critical areas of early stage medical device development. This allows Koa to fail fast or rapidly advance the venture as a de-risked startup.
Chairman & CEO of Edwards Lifesciences Corp (30-Year Financial, Insider Trades) Michael A Mussallem (insider trades) sold 22,850 shares of EW on 09/10/2019 at an average price of $214.9 a share. Continue reading...
Edwards Lifesciences was first featured in the IBD 50 Stocks To Watch column in November 2018. Since then, it's smashed the S&P; 500 return.
CVP, CFO of Edwards Lifesciences Corp (30-Year Financial, Insider Trades) Scott B. Ullem (insider trades) sold 7,500 shares of EW on 09/09/2019 at an average price of $225.74 a share. Continue reading...
Janus Henderson Forty Fund is a bottom-up investor in growth stocks. But it can't ignore macro risks like a technology cold war between the U.S. and China.
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
IRVINE, Calif. , Aug. 28, 2019 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, is ...
CVP, CFO of Edwards Lifesciences Corp (30-Year Financial, Insider Trades) Scott B. Ullem (insider trades) sold 7,500 shares of EW on 08/26/2019 at an average price of $213.44 a share. Continue reading...
Today we're going to take a look at the well-established Edwards Lifesciences Corporation (NYSE:EW). The company's...
Edwards Lifesciences (EW) initiated the Field Corrective Action after receiving reports of 17 injuries and a death from the use of the Sapien 3 Ultra delivery system.
Chairman & CEO of Edwards Lifesciences Corp (30-Year Financial, Insider Trades) Michael A Mussallem (insider trades) sold 22,850 shares of EW on 08/22/2019 at an average price of $216.7 a share. Continue reading...
Edwards Lifesciences stock dipped Thursday after the FDA recalled the company's heart-valve replacement, or TAVR, system following several injuries and a patient death during implantation.
The U.S. health regulator on Thursday categorized the recall of Edwards Lifesciences Corp's Sapien 3 Ultra delivery system as extremely serious, highlighting health risks associated with its use, but the products will remain on the market. The system is used to deliver and deploy a transcatheter heart valve to replace a diseased aortic valve without open-heart surgery. In July, the medical device maker sent a safety notice to customers and doctors, recommending that the balloon in the delivery system be inflated slowly and continuously when deploying the heart valve to avoid rupture.
Medical device maker Edwards Lifesciences Corp is recalling its Sapien 3 Ultra delivery system after burst balloons during implantation led to several injuries and a death, said the U.S. Food and Drug Administration on Thursday. The delivery system is used to deploy its Sapien 3 Ultra transcatheter heart valve to replace a diseased aortic valve without open-heart surgery.
The Food and Drug Administration reported Edwards Lifesciences (NYSE: EW ) has recalled Sapien 3 Ultra delivery system due to burst balloons during surgery. Reports first emerged in June that the company ...
Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bulls got a taste of victory Friday and returned from the weekend wanting more. With stocks jumping over 1% across the board this morning, the backdrop could be set for profitable long trades. Today we'll look at three stocks to buy offering breakout chart patterns.One development emboldening buyers is the weakness finally striking bond prices. It was bound to happen sometime given their meteoric rise and is easing the panic. The past month has seen a mad dash into fixed-income due to pessimism over economic growth and lower inflation expectations.Fortunately, the companies highlighted in today's gallery haven't cared one bit about plunging interest rates or inverted yield curves. They all boast super-strong trends and earnings growth that continues unabated.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 Cheap Dividend Stocks to Load Up On Behold, three breakout stocks to buy for the week. 3 Breakout Stocks to Buy: Edward Lifesciences (EW)Edwards Lifesciences (NYSE:EW) is a medical equipment company based out of Irvine, California. EW stock price has been virtually untouched during the recent ruckus and popped to a new record high Friday. The culprit for its extraordinary strength is the variable that always allows a stock to buck the general market trend: earnings.If Edwards Lifesciences continues to post record earnings numbers, why should it could up in the trade war and inverted yield curve drama?Source: ThinkorSwim Since its mid-July pole vault, EW stock has spent the last month building a textbook high-base pattern. The consolidation allowed the stock to digest its gains and build a foundation for its next ascent. With Friday's rally to the upper end of its range, an upside breakout looks imminent.Buy the November $220/$240 bull call spread for around $8.30. Fiserv (FISV)Though it hales from a completely different sector, the story behind Fiserv (NASDAQ:FISV) mirrors that of EW. Strong earnings lifted the Wisconsin-based provider of financial services technology to new heights last month, and we've since seen the formation of a textbook high base pattern.Source: ThinkorSwim Broad market weakness prove impotent in knocking FISV stock from its well-deserved perch. The few down days cropping up over the past month haven't been able to push FISV below its rising 20-day moving average. The 50-day and 200-day moving averages are also rising loyally beneath and reflect buyers' dominance across longer time frames. * 15 Growth Stocks to Buy for the Long Haul This morning's up-gap could be the breakout spectators have been waiting for. Buy the October $110/$115 bull call spread for around $1.80. Starbucks (SBUX)The final member of today's trio is Starbucks (NASDAQ:SBUX). It's on pace for a banner year, currently up 50% for 2019. It too has wholly sidestepped the drama playing out in the market. We have seen sporadic down days but nothing powerful enough to breach even the 20-day moving average.And that's saying something given the bloodbath elsewhere.Source: ThinkorSwim The holding pattern seen since last month's mighty earnings gap is a welcome development setting up a more sustainable breakout. While some time may be needed yet before SBUX stock is ready to run again, it's worth putting on your radar now. $100 is the level to watch. Once broken, buyers should come running.Upside call vertical spreads are a low-cost way to play here. Buy the November $100/$105 bull call spread for around $1.60.As of this writing, Tyler Craig didn't hold a position in any of the aforementioned securities. Check out his recently released Bear Market Survival Guide to learn how to defend your portfolio against market volatility. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Cheap Dividend Stocks to Load Up On * The 10 Biggest Losers from Q2 Earnings * 5 Dependable Dividend Stocks to Buy The post 3 Beautiful Breakout Stocks to Buy appeared first on InvestorPlace.
Heart valve systems from Edwards Lifesciences Corp and Medtronic Plc have been approved for use in a condition that restricts blood flow from the heart in patients at low-risk of death linked to open-heart surgeries, the U.S. FDA said on Friday. The Food and Drug Administration approved two of Edwards' transcatheter heart valve systems called Sapien 3 And Sapien 3 Ultra as well as Medtronic's Evolut Transcatheter Aortic Valve Replacement (TAVR)system.
Shares of Medtronic and Edwards Lifesciences jumped Friday after the Food and Drug Administration approved their TAVR heart-valve replacement systems for healthier and younger patients.
Frost Equity Growth Fund invests in secular, consistent and cyclical growth stocks. Here's why most of the fund's bets are on secular growers.
Heart-valve maker Edwards Lifesciences is extending gains after gapping up on its quarterly earnings report in late July.